I am an accomplished epidemiologist, who specializes in the principled use and development of advanced causal inference methods for answering pharmacepideiological research questions in numerous therapeutic areas. In the real-world evidence space, I have designed and conducted dermatology and oncology studies, the latter being those on high-risk non-muscle invasive bladder and advanced non-small cell lung cancer. I am currently an Observational Research Manager at Amgen contributing to studies that shape the benefit/risk profile of our bone products. I received an MPH and a PhD in Epidemiology from Columbia University Mailman School of Public Health where I had formal training epidemiological methods with a primary focus on causal inference methods.
Download my CV.
PhD in Epidemiology, 2023
Columbia University
MPH in Epidemiology, 2016
Columbia University
BA in Business communications, 2010
Richmond University
Responsibilities include:
Responsibilities include:
In a longitudinal study of nicotine vaping’s influence on cannabis initiation, we found that the positivity causal identification assumption was violated. Regardless, we still estimated the average treatment effect (ATE) and an analogue estimand that does not require the positivity assumption. The analogue, the incremental propensity score intervention (IPSI), was the difference in cannabis initiation risks had everyone’s odds of nicotine vaping been decreased up to 90% compared with observed nicotine vaping odds. Interpetations of results from the IPSI and the ATE were consistent with each other. That is, lower odds of nicotine vaping decreases cannabis initiation risks (IPSI), and nicotine vaping increases cannabis initiation risk (ATE). Researchers should consider using shift estimands like IPSI when the positivity assumption is violated.